Kaisa Health Group Holdings Limited (00876.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−191.2x

Market Cap

HKD 9.88B

MomentumView details →

1D Return

−2.00%

YTD Return

−44.00%

RSI (14)

47.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−191.2x

Market Cap

HKD 9.88B

RSI (14)

47.3

MomentumView details →

1D Return

−2.00%

YTD Return

−44.00%

ProfitabilityView details →

Gross Margin

38.90%

Net Margin

−24.77%

EBITDA Margin

−10.75%

ROE (TTM)

39.95%

ROA (TTM)

−7.49%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

+39.96%

EPS YoY

−20.41%

FCF YoY

+43.34%

Revenue CAGR 3Y

−10.11%

EPS CAGR 3Y

+0.00%

EBITDA YoY

+5.08%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−2.01x

Current Ratio

0.46x

Quick Ratio

0.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

520.54M

Net Income (TTM)

−128.94M

Op. CF (TTM)

—

Latest newsMore news →

Kaisa Health Group issued a profit warning, expecting its loss attributable to owners for the six months ended June 2026 to widen to no more than HK$65 million, compared with a restated loss of about HK$7.7 million in the same period last year.16d ago

Kaisa Health's subsidiary Qinghai Pharmaceutical obtained a drug registration certificate for Hydromorphone Hydrochloride Injection, becoming one of only three enterprises nationwide holding a valid production registration certificate for this product.39d ago

Similar companies

海泰新光688677.SH Avantor, Inc.AVTR Repligen CorporationRGEN Masimo CorporationMASI 圣湘生物688289.SH AptarGroup, Inc.ATR Find similar companies →

Latest newsMore news →

Kaisa Health Group issued a profit warning, expecting its loss attributable to owners for the six months ended June 2026 to widen to no more than HK$65 million, compared with a restated loss of about HK$7.7 million in the same period last year.16d ago Kaisa Health's subsidiary Qinghai Pharmaceutical obtained a drug registration certificate for Hydromorphone Hydrochloride Injection, becoming one of only three enterprises nationwide holding a valid production registration certificate for this product.39d ago